Raising awareness of new solutions in patient care
Inherent Biosciences Announces Podium Presentations at American Urological Association Annual Meeting 2022
New technology and diagnostics are needed for better assessment of male infertility. The mainstay of male factor infertility diagnosis is the standard semen analysis (sperm concentration, motility, and morphology) has changed very little over the last several decades and has been shown to have limited value. Here we complete a prospective analysis of men seeking fertility care using a newly available epigenetic sperm quality test (SpermQT).
Inherent Biosciences Awarded NIH SBIR Phase I Grant to commercialize innovative diagnosis of non-obstructive azoospermia
NOA is present in 10-15% of infertile men where no sperm are present in the ejaculate due to failure of sperm production (spermatogenesis). Thus, this Small Business Innovation Research (SBIR) project focuses on an intractable clinical problem for specialists in reproductive medicine seeking to treat severe male factor infertility due to NOA. Importantly, there is increasing evidence to show that certain causes of male infertility may be associated with an increased risk of serious health conditions.
Inherent Biosciences launches Path Fertility – Epigenetic Sperm Quality Test (SpermQT)
SpermQT analyzes epigenetic patterns (DNA methylation) on genes associated with sperm production, sperm maturation, and embryo development. The test was validated with data from over 2,000 semen samples showing a sensitivity of 84% in predicting the need for In Vitro Fertilization (IVF) treatment. A detailed white paper describing the development and validation of SpermQT is available for download at pathfertility.com. A manuscript is in preparation for peer reviewed publication.
Inherent Biosciences Raises Seed Round, adds Board Members and Clinical Advisors
Inherent Biosciences today announced its initial capital raise led by Morning Star Foundation with additional participation from MedMountain Ventures, Kickstart Funds, Park City Angels, Rhythm VC and several angel investors. With the initial funding, Inherent will launch a male infertility diagnostic to guide infertility treatment.
Inherent Biosciences Wins $256K NSF Grant to predict COVID-19 infection severity and treatment response
The variation in symptoms and outcomes for COVID-19 progression make it challenging for healthcare workers to triage patients accurately. The development of a DNA methylation-based test to predict the severity of COVID-19 infection has tremendous potential for managing current and future pandemics.